Abstract Number: 1236 • 2018 ACR/ARHP Annual Meeting
Peripheral-Blood B-Cell Subset Disturbances in Whipple’s Disease
Background/Purpose: Whipple’s disease (WD) is a rare, systemic, disease caused by the intracellular Gram-positive bacterium Tropheryma whipplei (TW). This ubiquitous commensal organism is transmitted among…Abstract Number: 1237 • 2018 ACR/ARHP Annual Meeting
What Is the Value of Synovial Biopsies for the Diagnosis of Septic Arthritis?
Background/Purpose: Synovial biopsies are increasingly performed for research purposes but also in clinical practice. The development of US guided procedure has made this procedure simpler.…Abstract Number: 1238 • 2018 ACR/ARHP Annual Meeting
The Effect of Antibiotic Therapy on Positive Culture Results Among Patients with Prosthetic Joint Septic Arthritis
Background/Purpose: Little is known about the effects of antibiotic therapy on synovial and blood culture results among patients with prosthetic joint septic arthritis (PJSA). In…Abstract Number: 1239 • 2018 ACR/ARHP Annual Meeting
Organisms Associated with Prosthetic Joint Septic Arthritis over the Past Two Decades: Data from a Single Tertiary Medical Center Located in the Northeastern United States
Background/Purpose: In recent years, joint replacement surgery (JRS) has become increasingly common. Prosthetic joint septic arthritis (PJSA) may complicate JRS in up to 1% of…Abstract Number: 1240 • 2018 ACR/ARHP Annual Meeting
Foot Osteomyelitis in Inflammatory Rheumatic Diseases: A Retrospective Observational Study
Background/Purpose: Foot involvement is frequently pointed by patients with chronic inflammatory rheumatic diseases (IRD), such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or psoriatic arthritis (PsA).…Abstract Number: 1241 • 2018 ACR/ARHP Annual Meeting
Pneumococcal Vaccination Quality Improvement Initiative within a Rheumatology Clinic at an Academic Medical Center
Background/Purpose: Rheumatology patients are at an increased risk of infection secondary to immunosuppressive medications used for disease management. However, vaccination is underutilized and rates remain…Abstract Number: 1242 • 2018 ACR/ARHP Annual Meeting
Rheumatologists Participating in the RISE Registry Succeeded in the First Year of the Merit-Based Incentive Payment System (MIPS)
Background/Purpose: Under the Medicare Access and CHIP Reauthorization Act (MACRA), rheumatologists face financial repercussions through the Merit-Based Incentive Payment System (MIPS) based on performance on…Abstract Number: 1243 • 2018 ACR/ARHP Annual Meeting
A Quality Improvement Initiative to Increase Adherence to Hydroxychloroquine Dosing Guidelines at an Academic Medical Center
Background/Purpose: In 2016, the American Academy of Ophthalmology published revised guidelines on HCQ dosing, recommending a maximum daily dose of 5mg/kg actual body weight as…Abstract Number: 1244 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Quality Improvement Project at UF Health Jacksonville Rheumatology Clinics
Background/Purpose: Hydroxychloroquine (HCQ) is a treatment option for lupus erythematosus and rheumatoid arthritis. The risk of retinopathy in the first 5 years of therapy is…Abstract Number: 1245 • 2018 ACR/ARHP Annual Meeting
Methotrexate Quality Improvement Project at UF Health Jacksonville Rheumatology Clinics
Background/Purpose: The diagnosis of interstitial lung disease (ILD) is comprised of a large group of respiratory disorders. ILD can lead to scarring of lung tissue.…Abstract Number: 1246 • 2018 ACR/ARHP Annual Meeting
Practices of Hydroxychloroquine Dosing Based on the American Association of Ophthalmology (AAO) 2016 Recommendations: A Single Center Experience
Background/Purpose: In March 2016, the AAO updated antimalarial medication screening recommendations for retinopathy prevention, with a recommended dose of hydroxychloroquine (HCQ) ≤5.0 mg/kg total body…Abstract Number: 1247 • 2018 ACR/ARHP Annual Meeting
Pharmacist-Managed Titration of Urate-Lowering Therapy to Streamline Gout Management
Background/Purpose: The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines.…Abstract Number: 1248 • 2018 ACR/ARHP Annual Meeting
Revisit an Old Question: Should Glucose-6-Phosphate Dehydrogenase Level be Checked in Patients with Rheumatic Diseases Prior to Initiating Certain Drugs?
ABSTRACT: Background/Purpose: Glucose 6 Phosphate Dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells, and its frequency varies among different ethnicities.…Abstract Number: 1249 • 2018 ACR/ARHP Annual Meeting
Contraception Compliance in Patients with Rheumatological Diseases on Disease Modifying Antirheumatic and Cytotoxic Drugs
Background/Purpose: Women of child bearing age with autoimmune diseases are often prescribed teratogenic medications as Methotrexate, Mycophenolate Mofetil, Leflunomide and Cyclophosphamide. Contraceptive compliance in this…Abstract Number: 1250 • 2018 ACR/ARHP Annual Meeting
An Evaluation of Utilization Patterns and Appropriateness of Laboratory Tests Among New Referrals to Rheumatologists: Choosing Unwisely!
Background/Purpose: Laboratory testing comprises the highest volume procedure in medicine and is therefore an important target for improving healthcare spending and efficiency. Unnecessary testing both…